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doi:10.1016/j.jfma.2011.01.002Background/Purpose: Although the incidence of asymptomatic small gastric submucosal
tumors increased gradually with routine medical health examination, there was little clinical
evidence for management consensus in these small gastric submucosal tumors including endo-
scopic ultrasound (EUS)-suspected gastric gastrointestinal stromal tumors (GISTs). We investi-
gated the clinical course of small EUS-suspected gastric GISTs and propose a cutoff value of
tumor size for treatment policy.
Methods: In this retrospective study, 50 patients with EUS-suspected gastric GISTs of sizes less
than 3 cm were enrolled and were followed up by EUS at least twice over a period of more than
24 months (range 24e101 months). An at least 20% increase of the maximal diameter of the
tumors was set as a significant change.
Results: Significant changes in tumor size were found during the follow-up in 14 patients
(28.0%). The one-dimensional 20% change corresponded well to 50% change in two-
dimensional area measurement (correlation coefficientZ 0.929). The receiver operating char-
acteristic curve analysis showed that the best cutoff size, associated with tumor progression,
was 1.4 cm having an 85.7% sensitivity, 86.1% specificity, and 86.0% accuracy. A larger tumorof Internal Medicine, National Taiwan University Hospital, Number 7, Chung-Shan South Road, Taipei,
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Follow-up of small GISTs 89size (35.7% vs. 2.8%, pZ 0.005) and irregular tumor margin on the EUS (71.4% vs. 0, pZ 0.004)
were two significant factors associated with the progression of tumor growth of small sus-
pected gastric GISTs.
Conclusion: Small EUS-suspected GISTs, larger than 1.4 cm, with irregular margin were associ-
ated with significant progression. This subgroup is suggested to be monitored by more intensive
follow-up.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Gastrointestinal stromal tumors (GISTs) are the most
common submucosal tumors (SMTs) found in the stomach.1
Because clinical symptoms are usually nonspecific, the true
incidence of either gastric GISTs or other gastric SMTs
remains unclear. Most such lesions are incidentally found
during routine endoscopic examination or at autopsy. One
previous study estimated the incidence of gastric SMTs to
be 0.36% by endoscopic diagnosis.2 However, several
studies have suggested an incidence of gastric GISTs
between 10 and 20 cases per million based on surgical and
autopsy specimens.3e5
Endoscopic ultrasound (EUS) has been used for the
evaluation of the SMTs of the stomach with a high accu-
racy.6e13 The typical EUS finding of a gastric GIST is
a hypoechoic lesion arising from the fourth layer of the
gastric wall. The diagnostic accuracy of gastric GISTs by
EUS alone (by experienced endoscopists) is as high as
87%.13e15 Several studies have proposed EUS characteristics
for predicting the malignant potential of GISTs, including
a larger size (more than 3 cm), heterogeneous echoge-
nicity, irregular borders, cystic changes, calcification,
exogastric growth, echogenic foci, lobulation, and
ulceration.11,13,16,17
Surgical intervention is the treatment of choice for
gastric GISTs larger than 2 cm, while conservative follow-up
is suggested for lesions less than 2 cm.18e20 EUS-guided
fine-needle aspiration (EUS-FNA), to exclude a malig-
nancy, was recommended for gastric GISTs of sizes between
2 and 5 cm.21,22 However, little is known about the natural
course of small EUS-suspected gastric GISTs. This makes the
decisions on interventions for smaller gastric GISTs difficult.
The tumor growth potential is an important index of
malignancy.23 The goal of this study was to evaluate the
natural course of small EUS-suspected gastric GISTs less
than 3 cm, a subgroup with consistent EUS features of
GISTs, but usually lacking histological confirmation at initial
diagnosis. The best cutoff size was determined for the
prediction of significant tumor growth. This would provide
clinicians with information needed for appropriate
intervention.
Methods
Study design and population
We retrospectively reviewed patients with a diagnosis of
suspected gastric GISTs by EUS at the National TaiwanUniversity Hospital, Yuan’s General Hospital, and En Chu
Kong Hospital from January 1997 to December 2008.
An EUS-suspected gastric GIST was defined as a hypo-
echoic lesion arising from the fourth layer of the gastric
wall shown on EUS. Written informed consents were
obtained from all patients before EUS studies. Miniprobes
(Olympus UM-2R, 12 MHz or UM-DP12-25R, 12 MHz;
Olympus, Tokyo, Japan) were used for the EUS examina-
tions in this study. All EUS images and video files were
reviewed by three experienced EUS endoscopists (HP Wang,
MS Sun, and CS Yang).
Four criteria were required for study enrollment: (1)
a small tumor size, less than 3 cm, without definite EUS
characteristics of malignancy such as extragastric growth
and lobulation; (2) patients declining surgical intervention
at initial identification of the lesions; (3) EUS follow-up
frequency of at least two times; (4) EUS follow-up period of
more than 24 months.
Study procedures and assessments
All clinical data and EUS characteristics were reviewed for
subsequent analysis. Patients with EUS-suspected GISTs,
less than 3 cm, were enrolled and followed up. The natural
course of tumor growth was evaluated by EUS. We set an
increase of at least 20% in the maximal diameter of the
tumors as progressive disease according to Response Eval-
uation Criteria in Solid Tumors (RECIST) criteria. Patients
were classified as the tumor-progressive subgroup when
a significant change in tumor size was noted or as the
tumor-stationary subgroup when no change was observed.
All two-dimensional (2D) measurements were assessed
using the image processing software ImageJ 1.41e (NIH,
USA).24
This study was conducted in accordance with National
Taiwan University Hospital research protocol, and was
approved by the Human Subjects Research Ethics
Committee of the National Taiwan University Hospital.
Statistical analysis
All statistical analyses were carried out with statistical
software (SPSS version 10.0 for Windows; SPSS, Chicago, IL,
USA). The sensitivity and specificity of various tumor sizes
were analyzed using the receiver operating characteristic
(ROC) curve, and the best cutoff value was determined.
The relationship between the study parameters and the
tumor size were analyzed using the Pearson chi-square test.
Statistical significance was set at the standard 5% level.
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Characteristics of patients and tumors
Fifty patients meeting the criteria for the diagnosis of EUS-
suspected GISTs were enrolled. The average initial tumor
size was 1.1 cm (range 0.4e3.0 cm). The mean EUS follow-
up period was 39.2 months (range 24e101 months). The
mean EUS follow-up frequency was 3.2 (range 2e9 times).
No significant change in echo patterns was observed in 41
patients (82.0%). Seven patients had undergone surgical
resection, and all their tumors proved to be GISTs.
With consideration of tumor progression, significant
change in tumor size was found in 14 patients (28.0%)
during the follow-up. Four of these 14 patients underwent
surgery, while the other 10 patients refused surgery and
were followed up regularly (at least once a year) for an
average of 51.2 months (range 33e101 months). Two of the
four patients undergoing surgery had lesions with high
malignant potential, reflected by mitotic rates of more
than 10 per 50 high-power fields (HPFs).
Demography of the 50 patients and various parameters
of small EUS-suspected GISTs are shown in Table 1. The
average tumor growth rate in this progressive disease groupTable 1 Demography and various parameters of small
EUS-suspected GISTs in 50 patients.
Parameter Stationary
disease
(n Z 36)
Progressive
disease
(n Z 14)
p
Age (yr)
&65 29 8 0.149
>65 7 6
Gender
Male 12 7 0.276
Female 24 7
Symptom
Asymptomatic 34 11 0.126
Symptomatic 2 3
Comorbidity
Present 7 1 0.414
Absent 29 13
Initial size (cm)
<2 35 9 0.005
S2 1 5
Location
Cardia to upper body 30 11 0.697
Middle body to antrum 6 3
Echogenicity
Homogeneous 34 11 0.126
Heterogeneous 2 3
Tumor margin
Regular/smooth 36 10 0.004
Irregular 0 4was 17.1% per year, which was significantly higher than 1.0%
per year in the stationary disease group (Fig. 1).
ROC curve evaluation
With the 2 cm cutoff, the lowest limit for resection
currently accepted, tumors of larger sizes would be
significantly associated with tumor progression (35.7% vs.
2.8%, p Z 0.005). Only one case with a tumor size of 2 cm
remained in the stationary size after 39 months of follow-
up. Since there was significant proportion of cases with
a tumor size smaller than 2 cm in the tumor progression
group, we performed an ROC curve analysis to determine
the best cutoff size for the prediction of potential tumor
growth (Fig. 2). We found 1.4 cm to be the best cutoff
tumor size associated with tumor progression, with
a sensitivity of 85.7%, specificity of 86.1%, positive predic-
tive value of 70.6%, negative predictive value of 93.9%, and
an accuracy of 86.0%.
Among the seven patients who underwent operation,
five patients had an initial tumor size larger than 1.4 cm,
and two of them (40%) belonged to the high risk group
(mitosis >10/50 HPFs). The other two patents with initial
tumor size smaller than 1.4 cm belonged to the very low
risk group (mitosis <5/50 HPFs).
Correlation between 1D and 2D evaluation
All EUS lesions were analyzed for 2D assessment with image
processing software ImageJ. The last EUS lesion during
follow-up was compared to the initial EUS lesion (Fig. 3). A
good linear relationship was shown during comparison
between percentage changes of 1D and 2D measurements
(Fig. 4). The 1D 20% change corresponded well toFigure 1 The average tumor growth rate in this progressive
disease group was significantly higher than that in the
stationary disease group.
Figure 2 Receiver operating characteristic curve was plotted with coordinates derived from various cutoff values.
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(correlation coefficient Z 0.929).
Risk factor analysis
The chi-square test was used to compare the parameters of
patients in the tumor-stationary group with those in the
tumor-progressive group. There were no significant differ-
ences observed with regard to age, gender, symptoms,
comorbidity, tumor location, and EUS echogenicity.Figure 3 The last endoscopic ultrasound (EUS) picture of one
patient during follow-up was compared to the initial EUS lesion
(left upper insert) with aid of ImageJ software for both one-
dimensional (1D) and 2D measurements.Patients in the tumor-progressive group had a higher
proportion of lesions with irregular tumor margin (Fig. 5) on
the EUS compared with patients in the tumor-stationary
group (71.4% vs. 0%, p Z 0.004).
After ROC curve analysis showed 1.4 cm to be the best
cutoff tumor size associated with tumor progression, we
performed the chi-square test again to confirm the associ-
ation of tumor size with tumor growth between smaller and
larger tumors. Larger tumors at least 1.4 cm in size were at
increased risk for tumor growth (70.6% vs. 6.1%, p<0.001)
and symptomatic presentation (23.5% vs. 3.0%, pZ 0.022),
and characterized with irregular tumor margins (23.5% vs.
3.0%, p Z 0.022).Discussion
GISTs are known to be the most common mesenchymal
neoplasm of the gastrointestinal tract. The stomachFigure 4 Good linear relationship was illustrated on
comparing percentage changes of 1D and 2D measurements.
Figure 5 EUS showed a small gastrointestinal stromal tumor
with irregular margin (arrow).
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common sites of GISTs.1,25,26 Despite the success of imati-
nib mesylate in the treatment of advanced GISTs, surgical
resection is still the treatment of choice for patients with
primary GISTs without evidence of metastases. Several risk
factors have been identified for predicting the aggressive
behavior of GISTs. Tumor size and mitotic activity were two
most well-documented factors in the National Institutes of
Health consensus.27 In addition, tumor location plays an
important role.28 Small bowel GISTs has higher progression
rates than gastric GISTs of similar tumor size and mitotic
activity.29
Because the natural course of small GISTs remains
largely unknown, the current management policy for
gastric GISTs less than 2 cm is usually conservative, unless
tumors grow or symptoms occur. EUS-guided FNA for the
determination of malignant potential has been suggested
for gastric GISTs with the size of 2e5 cm.22 The diagnostic
sensitivity, specificity, and accuracy of EUS-FNA have been
reported to be 66.7%, 100%, and 91.7%, respectively.21
However, it would be difficult to use EUS-FNA for all
gastric GISTs less than 2 cm from both technical and cost-
effective points of view.22 It should be noted though that
a more thorough and effective interventional strategy is
needed for small isolated gastric GISTs found incidentally
on endoscopy.
In this study, we evaluated the tumor characteristics of
small gastric GISTs, less than 3 cm, identified by EUS.
Among the 50 cases enrolled in this study, we evaluated the
association of the initial tumor size with tumor progression.
Most cases with a tumor size of at least 2 cm had a signifi-
cant progression of tumor growth. However, the widely
accepted “2 cm criteria” was not adequate for separating
the progressive tumors from the stationary ones in our
study. The ROC curve analysis identified 1.4 cm as the best
predictor of tumor progression with a good sensitivity
(85.7%), specificity (86.1%), and accuracy (86.0%). Further
confirmation of these findings is needed in a largermulticenter cohort. Our results are similar with those found
in the study conducted in Israel, which stated that GISTs
larger than 17 mm at initial diagnosis had potential
enlargement.30 However, our data were specific for GISTs of
the stomach, and our mean initial tumor size (average
11.1 mm) was smaller than that used in the Israel study
(average 20.5 mm). We adopted 1D assessment in this study
for its convenience in clinical practice, and this simplifi-
cation was in accordance with the idea of widely accepted
RECIST guidelines in the evaluation of tumor size.31 We
confirmed this 1D simplification to be as effective as 2D
measurement after linear correlation with image process-
ing software ImageJ.
In this study, we used EUS as the major imaging proce-
dure for monitoring tumor status. The EUS has previously
been identified as the most accurate tool for evaluating
gastric SMTs including GISTs.6e8 Previous studies have
proposed EUS characteristics associated with malignant
GISTs: larger size (more than 3 cm), heterogeneous echo-
genicity, irregular borders, the presence of cystic changes,
calcifications, exogastric growth, echogenic foci, lobula-
tion, and ulceration.11,13,16,17 Our findings were consistent
with these prior results and suggested that irregular tumor
margins were as important as tumor size in predicting
tumor progression in small gastric GISTs. However, we could
not confirm the significance of other EUS patterns between
the progressive and stationary groups of small EUS-
suspected gastric GISTs in our study.
The symptoms on presentation of the gastric GISTs were
usually nonspecific and depended on the size of lesions.
Symptoms associated with mass effects and bleeding were
the most common clinical presentations. One previous
report had estimated that the mean size of a symptomatic
tumor was 6.0 cm compared to the 2.0 cm size of tumors
found incidentally and the 0.5 cm size of those found at
autopsy.3 In one recent study, presentation with symptom
was associated with a poor 5-year disease-free survival (HR
2.5, p Z 0.04).32 In our study, the mean initial tumor size
was 1.1 cm. Symptomatic tumors accounted for only 10.0%
(5/50) of the patients in our series. Four patients had the
symptom of epigastralgia, and only one presented tarry
stool. Our results only showed a nonsignificant trend for
patients with symptomatic presentations to have
a progressive disease process. Further analysis between
tumor size effects and symptom presentation was not
possible because of the small case number in this study.
There are several limitations in this study. First, only
a portion (14%) of the EUS-suspected gastric GIST group had
pathological confirmation. Although previous studies
showed excellent correlation of the EUS features with
gastric CD117-positive GISTs,33 pathological confirmation
with immunohistochemical staining was the gold standard
for a definitive diagnosis. Further studies with the aid of
EUS-FNA may provide additional confirmation. Second, the
resolution of the videotape images for the evaluation of
echo features may not have been sharp enough at times in
this retrospective review. Third, tumor size alone is not
enough to predict aggressive behaviors in GISTs, but it is an
easy and reproducible index in clinical practice. The
current follow-up observation policy for GISTs of sizes less
than 2 cm made other indexes such as mitotic count
interpretation difficult to perform due to the lack of
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size criteria to a reasonable lower limit with a noninvasive
approach. Longer follow-up periods could justify this
refinement. Finally, there was no standard follow-up
program in our study groups.
Conclusion
To sum up, small EUS-suspected GISTs larger than 1.4 cm
and irregular tumor margin were associated with tumor
progression and probably increased malignant potential.
They should be monitored by more intensive follow-up
programs. Further prospective study with longer follow-up
period and EUS-FNA sampling could provide important
information on the natural course of small gastric GISTs and
possible treatment guidelines.
References
1. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs):
definition, occurrence, pathology, differential diagnosis and
molecular genetics. Pol J Pathol 2003;54:3e24.
2. Hedenbro JL, Ekelund M, Wetterberg P. Endoscopic diagnosis of
submucosal gastric lesions. The results after routine endos-
copy. Surg Endosc 1991;5:20e3.
3. Nilsson B, Bu¨mming P, Meis-Kindblom JM, Ode´n A, Dortok A,
Gustavsson B, et al. Gastrointestinal stromal tumors: the
incidence, prevalence, clinical course, and prognostication in
the preimatinib mesylate erada population-based study in
western Sweden. Cancer 2005;103:821e9.
4. Tryggvason G, Gı´slason HG, Magnu´sson MK, Jo´nasson JG.
Gastrointestinal stromal tumors in Iceland, 1990e2003: the
Icelandic GIST study, a population-based incidence and
pathologic risk stratification study. Int J Cancer 2005;117:
289e93.
5. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M,
Herings RM, Hogendoorn PC. Incidence of gastrointestinal
stromal tumours is underestimated: results of a nation-wide
study. Eur J Cancer 2005;41:2868e72.
6. Yasuda K, Nakajima M, Yoshida S, Kiyato K, Kawai K. The
diagnosis of submucosal tumors of the stomach by endoscopic
ultrasonography. Gastrointest Endosc 1989;35:10e5.
7. Caletti G, Zani L, Bolondi L, Brocchi E, Rollo V, Barbara L.
Endoscopic ultrasonography in the diagnosis of gastric submu-
cosal tumor. Gastrointest Endosc 1989;35:413e8.
8. Yasuda K, Cho E, Nakajima M, Kawai K. Diagnosis of submucosal
lesions of the upper gastrointestinal tract by endoscopic
ultrasonography. Gastrointest Endosc 1990;36:S17e20.
9. Buscarini E, Stasi MD, Rossi S, Silva M, Giangregorio F,
Adriano Z, et al. Endosonographic diagnosis of submucosal
upper gastrointestinal tract lesions and large fold gastro-
pathies by catheter ultrasound probe. Gastrointest Endosc
1999;49:184e91.
10. Hizawa K, Matsumoto T, Kouzuki T, Suekane H, Esaki M,
Fujishima M. Cystic submucosal tumors in the gastrointestinal
tract: endosonographic findings and endoscopic removal.
Endoscopy 2000;32:712e4.
11. Ro¨sch T, Kapfer B, Will U, Baronius W, Strobel M, Lorenz R,
et al. Accuracy of endoscopic ultrasonography in upper
gastrointestinal submucosal lesions: a prospective multicenter
study. Scand J Gastroenterol 2002;37:856e62.
12. Shim CS, Jung IS. Endoscopic removal of submucosal tumors:
preprocedure diagnosis, technical options, and results.
Endoscopy 2005;37:646e54.13. Brand B, Oesterhelweg L, Binmoeller KF, Sriram PV,
Bohnacker S, Seewald S, et al. Impact of endoscopic ultrasound
for evaluation of submucosal lesions in gastrointestinal tract.
Dig Liver Dis 2002;34:290e7.
14. Franquemont DW. Differentiation and risk assessment of gastro-
intestinal stromal tumors. Am J Clin Pathol 1995;103:41e7.
15. Chak A. EUS in submucosal tumors. Gastrointest Endosc 2002;
56:S43e8.
16. Chak A, Canto MI, Ro¨sch T, Dittler HJ, Hawes RH, Tio TL, et al.
Endosonographic differentiation of benign and malignant
stromal cell tumors. Gastrointest Endosc 1997;45:468e73.
17. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP.
Endosonographic features predictive of benign and malignant
gastrointestinal stromal cell tumours. Gut 2000;46:88e92.
18. Lai IR, Chen CN, Lin MT, Lee PH. Surgical treatment of gastric
gastrointestinal stromal tumors: analysis of 92 operated
patients. Dig Surg 2008;25:208e12.
19. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H,
et al. NCCN Task Force report: management of patients with
gastrointestinal stromal tumor (GIST)dupdate of the NCCN
clinical practice guidelines. J Natl Compr Cancer Netw 2007;5:
S1e29. quiz S30.
20. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. ESMO
Guidelines Working Group. Gastrointestinal stromal tumours:
ESMO clinical recommendations for diagnosis, treatment and
follow-up. Ann Oncol 2009;204:64e7.
21. Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T,
et al. The diagnosis of GI stromal tumors with EUS-guided fine
needle aspiration with immunohistochemical analysis. Gas-
trointest Endosc 2002;55:37e43.
22. Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M,
Yamamura Y, et al. Clinical practice guidelines for gastroin-
testinal stromal tumor (GIST) in Japan: English version. Int J
Clin Oncol 2008;13:416e30.
23. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;
100:57e70.
24. Rasband WS. ImageJ. Bethesda, MD, USA: U.S. National Insti-
tutes of Health, http://rsb.info.nih.gov/ij/; 1997e2005.
25. Urbanczyk K, Limon J, Korobowicz E, Chosia M, Sygut J,
Karcz D, et al. Gastrointestinal stromal tumors. A multicenter
experience. Pol J Pathol 2005;56:51e61.
26. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal
tumour. Lancet 2007;369:1731e41.
27. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J,
Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors:
a consensus approach. Hum Pathol 2002;33:459e65.
28. Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ. Prognosis of
gastrointestinal smooth-muscle (stromal) tumors: dependence
on anatomic site. Am J Surg Pathol 1999;23:82e7.
29. Tashiro T, Hasegawa T, Omatsu M, Sekine S, Shimoda T, Katai H.
Gastrointestinal stromal tumour of the stomach showing lymph
node metastases. Histopathology 2005;47:438e9.
30. Lachter J, Bishara N, Rahimi E, Shiller M, Cohen H, Reshef R.
EUS clarifies the natural history and ideal management of
GISTs. Hepatogastroenterology 2008;55:1653e6.
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS,
Rubinstein L, et al. New guidelines to evaluate the response to
treatment in solid tumors. European organization for research
and treatment of cancer, National cancer institute of the
United States, National cancer institute of Canada. J Natl
Cancer Inst 2000;92:205e16.
32. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal
tumor: 5 years later. Cancer 2005;104:1781e8.
33. Hassan I, You YN, Shyyan R, Dozois EJ, Smyrk TC, Okuno SH,
et al. Surgically managed gastrointestinal stromal tumors:
a comparative and prognostic analysis. Ann Surg Oncol 2008;
15:52e9.
